Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-101 in Relapsed or Refractory B-cell Malignancies
NCT05753501Phase 1Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jun 2023
- Primary completion
- Mar 2031
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 9
01
Overview
Phase 1, open-label, single-arm trial of ABBV-101 in non-Hodgkin lymphoma (NHL), sponsored by AbbVie Inc. Primary endpoints: Number of Participants with Adverse Events at 88 months, Change in Laboratory Parameters at 88 months and 2 more. Started Jun 2023; status: active, not recruiting.
02
Drugs
ABBV-101
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT05753501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05753501.